KRAS and cancer: We thus investigated the anti-cancer potency of the combinatorial regime of KRAS ASO and immRNA delivered by RBCEVs to various KRAS mutation-bearing cancer cell types, including A427 lung cancer cells (KRAS G12D), AsPC-1 pancreatic cancer cells (KRAS G12D), PDO67 patient-derived pancreatic cancer cells (KRAS G12D), CT26 colorectal cancer cells (Kras G12D), and H441 lung cancer cells (KRAS G12V).